Leon A. Boston
CEO Mobile, ODT
Leon A. Boston is a senior MedTech executive with over two decades of experience in leadership positions in the healthcare industry. Leon has an extensive track record of success, specializing in introducing novel medical technologies to the world healthcare markets, while taking them through all the aspects of growth and commercialization.
As a CEO of MobileODT, Leon leverages his vast experience, to transform the company into a scalable business entity, based on Artificial Intelligence (AI) and Machine Learning (ML) algorithms, while revolutionizing the cervical cancer screening and diagnosis process.
MobileODT is the only company to use AI as a screening tool for cervical cancer. The strategic direction of MobileODT is to evolve into a fully encompassing digital health company built on the foundations of AI. With further applications in women’s wellness and fertility under development, MobileODT is evolving as a leading Femtech company transforming lives and changing outcomes for women world-wide.
Their Visual Check AI technology is supporting a large-scale government cervical cancer screening project in the Dominican Republic.
MobileODT will partner with Genworks and Apollo Hospitals to deliver its FDA-cleared smart mobile colposcope in India. The project will perform the first large-scale pilot of Augmented Intelligence (AI) for use in the screening of cervical cancer. Over 432 million women in India are at risk of developing cervical cancer, yet only 3.1% receive screening. This will be the most comprehensive and largest cervical cancer screening program performed in India, to date.
Leon A. Boston is a senior MedTech executive with over two decades of experience in leadership positions in the healthcare industry. Leon has an extensive track record of success, specializing in introducing novel medical technologies to the world healthcare markets, while taking them through all the aspects of growth and commercialization.
As a CEO of MobileODT, Leon leverages his vast experience, to transform the company into a scalable business entity, based on Artificial Intelligence (AI) and Machine Learning (ML) algorithms, while revolutionizing the cervical cancer screening and diagnosis process.
MobileODT is the only company to use AI as a screening tool for cervical cancer. The strategic direction of MobileODT is to evolve into a fully encompassing digital health company built on the foundations of AI. With further applications in women’s wellness and fertility under development, MobileODT is evolving as a leading Femtech company transforming lives and changing outcomes for women world-wide.
Their Visual Check AI technology is supporting a large-scale government cervical cancer screening project in the Dominican Republic.
MobileODT will partner with Genworks and Apollo Hospitals to deliver its FDA-cleared smart mobile colposcope in India. The project will perform the first large-scale pilot of Augmented Intelligence (AI) for use in the screening of cervical cancer. Over 432 million women in India are at risk of developing cervical cancer, yet only 3.1% receive screening. This will be the most comprehensive and largest cervical cancer screening program performed in India, to date.
